VivoSeq
Other

Pain

140

Pipeline Programs

49

Active Trials

75

Companies Involved

Pain is a highly competitive landscape with 140 programs across 75 companies. The most active players are Sanofi, Averitas Pharma, Inc., Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. 80 therapies are approved with 18 more in late-stage development.

Pipeline Metrics

Competitive Density

76/100

Pipeline Velocity

56/100

Mech. Concentration

13/100

Completion Rate

83/100

Attrition Rate

11/100

Programs by Phase

Modality Breakdown

95%

Small molecule

134 of 141 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody43%Protein / enzyme21%Peptide1<1%

Small molecule leads; the ring shows all 141 classified programs, each share of the total. Modality classified for 94% of 151 pipeline programs.

Trial Status

219

clinical trials

Completed120 · 55%
Recruiting31 · 14%
Unknown status25 · 11%
Terminated12 · 5%
Withdrawn11 · 5%
Not yet recruiting9 · 4%
Other11 · 5%

Trial Activity

219 trials

Pain After Buffered Vs Non Buffered Articaine
Recruiting·CCleveland Dental Institute·Phase 2·NCT06538233·108 enrolled
Scheduled or As Needed Pain Regimen?
Recruiting··Phase 4·NCT06495632·90 enrolled
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
Recruiting··Phase 2·NCT03984565·25 enrolled
Dronabinol as an Adjunct for Reducing Pain
Recruiting··Phase 2·NCT06454669·75 enrolled
Ginger Root Extract for Sciatic Pain Individuals
Recruiting··Phase 2·NCT06817018·80 enrolled
Low Dose Naltrexone for Pain in Patients With HIV
Recruiting·EEmory University·Phase 4·NCT05537935·60 enrolled
Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)